Patents by Inventor Allen A. Fienberg

Allen A. Fienberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20240041871
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Application
    Filed: October 4, 2023
    Publication date: February 8, 2024
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20230355616
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson’s disease or any combinations.
    Type: Application
    Filed: February 15, 2023
    Publication date: November 9, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
  • PDE1 inhibitors for ophthalmic disorders
    Patent number: 11464781
    Abstract: Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure-lowering agents. Topical and systemic therapy may be used.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: October 11, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Robert Davis, Allen Fienberg
  • NOVEL DEVICES
    Publication number: 20220125791
    Abstract: Disclosed herein are novel drug eluting contact lenses configured to release one or more compounds that inhibit phosphodiesterase 1 (PDE1). The PDE1 inhibitors may be administered as monotherapy or in combination with additional pharmaceutical agents in the treatment of an ophthalmic disease, disorder or injury. Related methods of use and treatment are also disclosed.
    Type: Application
    Filed: January 28, 2020
    Publication date: April 28, 2022
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Robert DAVIS, Allen A. FIENBERG
  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20200405713
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Application
    Filed: July 6, 2020
    Publication date: December 31, 2020
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
  • Methods and compositions for sleep disorders and other disorders
    Patent number: 10702522
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: July 7, 2020
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Allen Fienberg, Lawrence P. Wennogle
  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20190183888
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Application
    Filed: October 19, 2018
    Publication date: June 20, 2019
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
  • Organic compounds
    Patent number: 10238660
    Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 26, 2019
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Allen A. Fienberg, Lawrence P. Wennogle, Sharon Mates
  • Methods and compositions for sleep disorders and other disorders
    Patent number: 10117867
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: November 6, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Allen Fienberg, Lawrence P. Wennogle
  • ORGANIC COMPOUNDS
    Publication number: 20180280396
    Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
    Type: Application
    Filed: June 4, 2018
    Publication date: October 4, 2018
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Allen A. FIENBERG, Lawrence P. WENNOGLE, Sharon MATES
  • Organic compounds
    Patent number: 10010553
    Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: July 3, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Allen A. Fienberg, Lawrence P. Wennogle, Sharon Mates
  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20170189398
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 6, 2017
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
  • Methods and compositions for sleep disorders and other disorders
    Patent number: 9616061
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: April 11, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle
  • ORGANIC COMPOUNDS
    Publication number: 20160375028
    Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Inventors: Allen A. Fienberg, Lawrence P. Wennogle, Sharon Mates
  • Organic compounds
    Patent number: 9468637
    Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: October 18, 2016
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Allen A. Fienberg, Lawrence P. Wennogle, Sharon Mates
  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20160030425
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Application
    Filed: October 16, 2015
    Publication date: February 4, 2016
    Inventors: Sharon MATES, Allen FIENBERG, Lawrence WENNOGLE
  • Organic compounds
    Patent number: 9198924
    Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment and/or prophylaxis of narcolepsy.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: December 1, 2015
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Allen A. Fienberg
  • Methods and compositions for sleep disorders and other disorders
    Patent number: 9168258
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: October 27, 2015
    Assignee: INTRA-CELLULAR THERAPRIES, INC.
    Inventors: Sharon Mates, Allen Fienberg, Lawrence P. Wennogle
  • Method of treating female sexual dysfunction with a PDE1 inhibitor
    Patent number: 9006258
    Abstract: The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and/or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female sexual dysfunction.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: April 14, 2015
    Assignee: Intra-Cellular Therapies, Inc.
    Inventors: Allen A. Fienberg, Sharon Mates, Lawrence P. Wennogle
  • Methods and compositions for sleep disorders and other disorders
    Patent number: RE48839
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: December 7, 2021
    Assignee: Intra-Cellular Therapies, Inc
    Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle